Gary Giarratano joins Radient Pharmaceuticals

Takes position of director of North American sales and marketing

Radient Pharmaceuticals Corporation (RPC) has appointed Gary Giarratano as director of North American sales and marketing. He will also be responsible for managing sales of the firm’s Onko-Sure in vitro diagnostic (IVD) cancer test.

Armed with a successful track record in the IVD industry, Giarratano brings more than 20 years of healthcare, sales and marketing leadership experience to the California-based firm. He is recognised for his contributions in new market development for Carcinoembryonic Antigen (CEA), PSA and HPV and led sales for the first company to secure US FDA approval on each of these assays.

‘Gary thoroughly understands the intricacies of the IVD marketplace and has repeatedly successfully driven market share for various new test kit products. We expect him to do the same for Onko-Sure,’ said Douglas MacLellan, ceo of RPC.

You may also like

Ingredients
UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny

UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny

The agency's new biomonitoring study will investigate PFAS exposure across the UK, providing evidence as pharmaceutical manufacturers face growing pressure around the use of forever chemicals
You need to be a subscriber to read this article.
Click here to find out more.
Packaging
Embracing healthcare innovation with 2D codes

Embracing healthcare innovation with 2D codes

Pharmaceutical manufacturers already serialise medicines using 2D codes to meet regulatory requirements, but a 2D code can be so much more than a tick box for compliance, explains Ian Chapman, Strategic Manager for Digital Coding at Domino Printing Sciences
Manufacturing
Pace Life Sciences completes EMA GMP inspection at New Jersey CDMO facility

Pace Life Sciences completes EMA GMP inspection at New Jersey CDMO facility

The inspection supports renewal of the EU GMP certificate at the company's New Jersey site, which provides pharmaceutical analytical testing, microbiology and development services
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing
UK Budget 2026: what it means for pharma manufacturing

UK Budget 2026: what it means for pharma manufacturing

VAT relief on free medicines, £1bn in new investment and revised capital allowances give pharma manufacturers progress — but gaps remain
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory
A completed reply is not a finalised case: how to test AI intake in pharma

A completed reply is not a finalised case: how to test AI intake in pharma

A medical information response marked complete says nothing about safety information that arrives later. Before accepting an AI intake demonstration, ask to see what happens to the next message: who assesses it, what stays pending and which dates are preserved
Manufacturing
Why CAPA keeps failing and what strong organisations do differently

Why CAPA keeps failing and what strong organisations do differently

This white paper examines why CAPA systems often close records without preventing recurrence, tracing breakdowns to investigation quality, risk reasoning, and organisational behaviour rather than procedural gaps. It outlines what differentiates compliant CAPA programmes from those that consistently reduce repeat findings and inspection risk
Manufacturing
Viewlinc Cloud Suite supports life science innovation from laboratory to regulated operations

Viewlinc Cloud Suite supports life science innovation from laboratory to regulated operations

Cloud-based environmental monitoring helps life science organisations establish professional-quality monitoring from day one and scale as requirements evolve
Subscribe now